Marginal parental donors for pediatric living donor liver transplantation.
Journal
Current opinion in organ transplantation
ISSN: 1531-7013
Titre abrégé: Curr Opin Organ Transplant
Pays: United States
ID NLM: 9717388
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
entrez:
10
11
2022
pubmed:
11
11
2022
medline:
15
11
2022
Statut:
ppublish
Résumé
Living donor liver transplantation (LT) has been increasingly recognized as an effective treatment modality with excellent patient survival. Indications for LT have evolved not only for cholestatic liver disease, but also metabolic liver diseases. Living donor selection, particularly for pediatric inherited disease, is essential to prevent morbidity, both in the donor and recipient. Based on 30 years of experience in pediatric living donor LT in Japan, we could identify marginal parental living donors who have potential risks following LT, including heterozygous mothers with ornithine transcarbamylase deficiency, heterozygous protein C deficiency, heterozygous hypercholesterolemia, heterozygous protoporphyria, asymptomatic parental donors with paucity of intrahepatic bile duct, and human leukocyte antigen-homozygous parental donors. Although these situations seem rare due to infrequency of the condition, careful living donor evaluation is required to optimize the outcomes for pediatric recipients. In the setting of an appropriate selection of a living donor, we should avoid any additional hazards, given that the procedure itself has risks for a healthy individual.
Identifiants
pubmed: 36354261
doi: 10.1097/MOT.0000000000000990
pii: 00075200-202208000-00016
doi:
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
346-350Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Tran L, Humar A. Current status of adult liver transplantation: utilization of living donor versus deceased donor graft. Curr Opin Organ Transplant 2021; 26:133–138.
Kasahara M, Katono M, Schlegel A, et al. Waiting list mortality for pediatric deceased donor liver transplantation in a Japanese living-donor–dominant program. Pediatr Transplant 2019; 23:e13578.
Kwong AJ, Kim WR, Lake R, et al. OPTN/SRTR 2019 Annual Data Report: Liver. Am J Transplant 21:S2:1-108.
Chen CL, Kabiling CS, Concejero AM. Why does living donor liver transplantation flourish in Asia? Nat Rev Gastroenterol Hepatol 2013; 10:746–751.
Oswari H, Rahayatri TH, Soedibyo S. Pediatric living donor liver transplant in Indonesia's national referral hospital. Transplantation 2020; 104:1305–1307.
Tran L, Humar A. Expanding living donor liver transplantation in the Western world: changing the paradigm. Dig Med Res 2020; 3:52–60.
Squires RH, Ng V, Romero R, et al. Evaluation of the pediatric patient for liver transplantation: 2014 Practice Guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. Hepatology 2014; 60:362–398.
McKiernan PJ, Ganoza A, Suires ES, et al. Evolving trends in liver transplant for metabolic liver disease in the United States. Liver Transplant 2019; 25:911–921.
Kasahara M, Umeshita K, Eguchi S, et al. Outcomes of pediatric liver transplantation in Japan: A report from the Japanese Liver Transplantation Society (JLTS). Transplantation 2021; 105:2587–2595.
Pham TA, Enns GM, Esquivel CO. Living donor liver transplantation for inborn errors of metabolism- An underutilized resource in the United States. Pediatr Transplant 2016; 20:770–773.
Kasahara M, Sakamoto S, Horikawa R, et al. Living donor liver transplantation for pediatric patients with metabolic disorders: The Japanese multicenter registry. Pediatr Transplant 2014; 18:6–15.
Nagata N, Mastuda I, Oyanagi K, et al. Estimated frequency of urea cycle enzymopathies in Japan. Am J Med Genet 1991; 39:228–229.
Rahayatri TH, Uchida H, Sasaki K, et al. Hyperammonemia in ornithine transcarbamylase-deficient recipients following living donor liver transplantation from heterozygous carrier donors. Pediatr Transplant 2017; 21:e12848.
Nightingale S, Raiman JA, Cutz E, et al. Late-onset ornithine transcarbamylase deficiency presenting with asymptomatic liver dysfunction. J Pediatr Gastroenterol Nutr 2014; 58:e55–57.
Esmon CT. The protein C pathway. Chest 2003; 124:S26–32.
Underberg JA, Cannon CP, Larry D, et al. Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER). J Clin Lipidol 2020; 14:807–817.
Kirnap NG, Kirnap M, Tutuncu NB, et al. The curative treatment of familial hypercholesterolemia: liver transplantation. Clin Transplant 2019; 33:e13730.
Kawagishi N, Satoh K, Enomoto Y, et al. Two cases in one family of living donor liver transplantation for homozygous familial hypercholesterolemia. J Gastroenterol 2006; 41:501–502.
Khalifeh M, Faraj W, Heaton N, et al. Successful living-related liver transplantation for familial hypercholesterolemia in the Middle East. Transplant Int 2005; 17:735–739.
Bonkovsky HL, Maddukuri VC, Yazici C, et al. Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. Am J Med 2014; 127:1233–1241.
Lissing M, Nowak, Adam R, et al. Liver transplantation for acute intermittent porphyria. Liver Transplant 2020; 27:491–501.
Singal AK, Parker C, Bowden C, et al. Liver transplantation in the management of porphyria. Hepatology 2014; 60:1082–1089.
Nunomura K. Prevention of manifestation of porphyrias in the field of digestive tract surgery: abnormal porphyrin metabolism and early diagnosis of acute intermittent porphyria. St Marianna Med J 1996; 24:593–601.
Al-Samkari, Patel AA, Kuter DJ. Recurrence of acute intermittent porphyria after liver transplantation. Ann Intern Med 2019; 170:904–905.
Saruwatari H, Ueki Y, Yotsumoto S, et al. Genetic analysis of the ferrochelatase gene in eight Japanese patients from seven families with erythropoietic protoporphyria. J Dermatol 2006; 33:603–608.
Wahlin S, Stal P, Adam R, et al. Liver transplantation for erythropoietic protoporphyria in Europe. Liver Transplant 2011; 17:1021–1026.
Minagawa K, Kayahara T, Ueda Y, et al. A case of erythropoietic protoporphyria with severe liver dysfunction. Jap J Gastroenterol 2011; 108:799–804.
Valamparampil JV, Reddy MS, Shanmugam N, et al. Living donor liver transplantation in Alagille syndrome-single center experience from south Asia. Pediatr Transplant 2019; 23:e13579.
Kasahara M, Kuichi T, Inomata Y, et al. Living-related liver transplantation for Alagille syndrome. Transplantation 2003; 75:2147–2150.
Kamei H, Oike F, Fujimoto Y, et al. Fatal graft-versus-host disease after living donor liver transplantation: Differential impact of donor-dominant one-way HLA matching. Liver Transplant 2006; 12:140–145.
Inaba H, Araki N, Hamanaka Y, et al. Frequency of HLA-class I and class II homozygous cells in Japanese. Jap J Transfusion Med 1995; 41:1–7.
Kruskall MS, Alper CA, Awdeh Z, et al. HLA-homozygous donors and transfusion-associated graft-versus-host disease. Letter to editor. N Engl J Med 1990; 322:1005–1006.
Kaplan A, Rosenbalatt R, Samstein B, Brown RS. Can living donor liver transplant in the United States reach its potential? Liver Transplant 2021; 27:1644–1652.
Angelico R, Trapani S, Spada M, et al. A national mandatory-split liver policy: a report from the Italian experience. Am J Transplant 2019; 19:2029–2043.
Yoeli D, Jackson WE, Adams MA, et al. Challenging the traditional paradigm of supply and demand in pediatric liver transplantation through nondirected living donation: a case series. Liver Transplant 2021; 27:1392–1400.
Klair T, Halff G, Fritze D, et al. Liver exchange using compatible pairs-US single center experience. Ann Surg 2020; 272:e282–283.
Wei Qu, Lin Wei, Zhi-Jun Zhu, et al. Consideration for use of domino cross-auxiliary liver transplantation in metabolic liver diseases: a review of case studies. Transplantation 2019; 103:1916–1920.
Raghu V, Carr-Boyd PD, Squires JE, et al. Domino transplantation for pediatric liver recipients: obstacles, challenges, and successes. Pediatr Transplant 2021; 25:e14114.
Shumizu S, Sakamoto S, Fukuda A, et al. Surgical technique and the long-term outcomes of pediatric living donor domino liver transplantation from patients with maple syrup urine disease. Pediatr Transplant 2021; 23:e14174.
Khanna A, Gish R, Winter SC, et al. Successful domino liver transplantation from a patient with methylmalonic acidemia. JIMD Rep 2016; 25:87–94.